nsclc: how to handle alk resistance
Published 2 years ago • 757 plays • Length 13:18Download video MP4
Download video MP3
Similar videos
-
30:46
nsclc: alk a rare fusion, yet so many options
-
26:57
segment 2: molecular targets in nsclc
-
21:51
eml4/alk and ros-1: how do we sequence therapies
-
22:10
first and second generation alk inhibitors for the treatment of lung cancer
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
28:17
segment 1: egfr tkis in nsclc
-
32:32
the era of adcs in the treatment of nsclc
-
21:35
colorectal cancer: msi testing to all patients and how to test
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
6:17
introduction to alk inhibitors
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
31:03
nsclc alk case base discussion series
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
26:13
therapeutic algorithm for nsclc adenocarcinoma
-
11:38
debate: alk positive nsclc - front line therapy - ceritinib
-
6:27
alk inhibitor sequencing in nsclc
-
13:28
debate: alk positive nsclc - front line therapy - crizotinib
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
20:24
targeted treatment with egfr tkis: front line options
-
1:01
what is an alk-positive cancer?